Douglas A. Stewart

7.1k total citations
208 papers, 4.8k citations indexed

About

Douglas A. Stewart is a scholar working on Pathology and Forensic Medicine, Oncology and Hematology. According to data from OpenAlex, Douglas A. Stewart has authored 208 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Pathology and Forensic Medicine, 79 papers in Oncology and 47 papers in Hematology. Recurrent topics in Douglas A. Stewart's work include Lymphoma Diagnosis and Treatment (85 papers), Hematopoietic Stem Cell Transplantation (34 papers) and Chronic Lymphocytic Leukemia Research (30 papers). Douglas A. Stewart is often cited by papers focused on Lymphoma Diagnosis and Treatment (85 papers), Hematopoietic Stem Cell Transplantation (34 papers) and Chronic Lymphocytic Leukemia Research (30 papers). Douglas A. Stewart collaborates with scholars based in Canada, United States and Switzerland. Douglas A. Stewart's co-authors include Nizar J. Bahlis, Peter Duggan, Adnan Mansoor, Jan Storek, Michael Crump, Diana Quinlan, David Mitchell, Carolyn Owen, James A. Russell and Andrew Daly and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Douglas A. Stewart

193 papers receiving 4.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Douglas A. Stewart Canada	38	1.6k	1.6k	1.6k	893	815	208	4.8k
A. H. Goldstone United Kingdom	33	1.6k 1.0×	1.4k 0.9×	1.6k 1.0×	855 1.0×	629 0.8×	101	3.9k
Mehdi Hamadani United States	37	1.7k 1.1×	2.5k 1.6×	3.4k 2.2×	890 1.0×	337 0.4×	411	6.2k
Jerzy Hołowiecki Poland	28	1.1k 0.7×	1.8k 1.2×	1.4k 0.9×	1.5k 1.7×	313 0.4×	139	4.8k
Thomas G. Gross United States	37	1.4k 0.9×	974 0.6×	2.1k 1.3×	353 0.4×	524 0.6×	127	4.3k
Jane N. Winter United States	40	3.6k 2.2×	846 0.5×	3.3k 2.1×	1.4k 1.5×	987 1.2×	257	7.0k
Keizo Horibe Japan	45	926 0.6×	3.1k 2.0×	1.6k 1.0×	645 0.7×	623 0.8×	282	6.7k
E. Thiel Germany	46	1.2k 0.7×	2.1k 1.3×	1.7k 1.1×	1.4k 1.5×	849 1.0×	208	6.9k
Mohamed A. Kharfan‐Dabaja United States	34	887 0.5×	2.2k 1.4×	1.7k 1.1×	882 1.0×	189 0.2×	313	4.5k
Olivier Tournilhac France	36	1.9k 1.2×	1.5k 1.0×	1.5k 1.0×	1.5k 1.7×	178 0.2×	180	4.8k
Andishe Attarbaschi Austria	33	980 0.6×	1.1k 0.7×	942 0.6×	304 0.3×	412 0.5×	155	3.4k

Countries citing papers authored by Douglas A. Stewart

Since Specialization

Citations

This map shows the geographic impact of Douglas A. Stewart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas A. Stewart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas A. Stewart more than expected).

Fields of papers citing papers by Douglas A. Stewart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas A. Stewart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas A. Stewart. The network helps show where Douglas A. Stewart may publish in the future.

Co-authorship network of co-authors of Douglas A. Stewart

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas A. Stewart. A scholar is included among the top collaborators of Douglas A. Stewart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas A. Stewart. Douglas A. Stewart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Puckrin, Robert, et al.. (2025). Impact of Underlying Disease and Total Body Irradiation on the Incidence of Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 31(3). 176.e1–176.e8.

Thành, Nguyễn Xuân, et al.. (2025). Impact of the COVID-19 pandemic on mortality and treatment costs of patients with colorectal cancer. Journal of Cancer Policy. 44. 100592–100592.

Stewart, Douglas A., John Kuruvilla, David M. Lee, et al.. (2024). Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre‐autologous stem cell transplant in relapsed/refractory diffuse large B‐cell lymphoma—outcome of rituximab‐dose‐intensive cyclophosphamide, etoposide, cisplatin (R‐DICEP) versus R‐GDP. British Journal of Haematology. 205(3). 881–890.

Puckrin, Robert, Neil Chua, Carolyn Owen, et al.. (2023). Consolidative Autotransplantation Achieves High Cure Rates in Adverse-Risk Large B Cell Lymphoma. Transplantation and Cellular Therapy. 29(12). 763.e1–763.e5.

Mansoor, Adnan, et al.. (2023). Unraveling the molecular landscape: a comparative analysis of PI3K and MAPK signaling pathways in plasmablastic lymphoma and diffuse large B-cell lymphoma with therapeutic implications. Human Pathology. 141. 102–109. 1 indexed citations

Thành, Nguyễn Xuân, et al.. (2023). Return on investment of the lymphoma diagnostic pathway implementation in Alberta, Canada. Leukemia & lymphoma. 64(7). 1253–1261. 1 indexed citations

Mansoor, Adnan, et al.. (2023). Primary testicular lymphoma demonstrates overexpression of the Wilms tumor 1 gene and different mRNA and miRNA expression profiles compared to nodal diffuse large B‐cell lymphoma. Hematological Oncology. 41(5). 828–837. 1 indexed citations

Tripathi, Gaurav, Poonam Dharmani‐Khan, Robert Puckrin, et al.. (2022). Incomplete chimerism following myeloablative and anti-thymocyte globulin-conditioned hematopoietic cell transplantation is a risk factor for relapse and chronic graft-versus-host disease. Cytotherapy. 24(12). 1225–1231. 2 indexed citations

Ghosh, Sunita, Catherine Leyshon, Deonne Dersch‐Mills, et al.. (2022). Toward optimization of cyclosporine concentration target to prevent acute graft‐versus‐host disease following myeloablative allogeneic stem cell transplant. Clinical Transplantation. 36(8). e14732–e14732. 4 indexed citations

10.

Walker, Emily, Yunting Fu, Daniel Sadowski, et al.. (2021). Delayed Colorectal Cancer Diagnosis during the COVID-19 Pandemic in Alberta: A Framework for Analyzing Barriers to Diagnosis and Generating Evidence to Support Health System Changes Aimed at Reducing Time to Diagnosis. International Journal of Environmental Research and Public Health. 18(17). 9098–9098. 11 indexed citations

11.

Stewart, Douglas A., et al.. (2020). Real World Characteristics and Outcomes of Patients with Relapsed and Refractory Diffuse Large B Cell Lymphoma; A Provincial Experience. Blood. 136(Supplement 1). 17–18. 1 indexed citations

12.

Lee‐Ying, Richard M., et al.. (2018). Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world. Leukemia & lymphoma. 60(1). 133–141. 19 indexed citations

13.

Davidson, Marta, Douglas A. Stewart, Peter Duggan, Andrew Daly, & Mona Shafey. (2017). Phase I/II Study of Infusional Gemcitabine and High-Dose Melphalan Conditioning Prior to Autologous Stem Cell Transplantation for Patients with Relapsed/Refractory Lymphoma: Interim Safety Analysis. Blood. 130. 4534–4534. 1 indexed citations

14.

Podgorny, Peter, Yiping Liu, Poonam Dharmani‐Khan, et al.. (2015). Low Counts of B Cells, Natural Killer Cells, Monocytes, Dendritic Cells, Basophils, and Eosinophils are Associated with Postengraftment Infections after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 22(1). 37–46. 16 indexed citations

15.

Thirukkumaran, Chandini M., Zhong Qiao Shi, Joanne Luider, et al.. (2012). Reovirus as a Viable Therapeutic Option for the Treatment of Multiple Myeloma. Clinical Cancer Research. 18(18). 4962–4972. 60 indexed citations

16.

Geddes, Michelle, Diana Quinlan, M. Ahsan Chaudhry, et al.. (2008). High Busulfan Exposure Is Associated with Worse Outcomes in a Daily i.v. Busulfan and Fludarabine Allogeneic Transplant Regimen. Biology of Blood and Marrow Transplantation. 14(2). 220–228. 101 indexed citations

17.

Stewart, Douglas A., Nizar J. Bahlis, Karen Valentine, et al.. (2006). Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 107(12). 4623–4627. 21 indexed citations

18.

Zweig, Richard A., Lawrence J. Siegel, Steven R. Hahn, et al.. (2005). Doctoral Clinical Geropsychology Training in a Primary Care Setting. Gerontology & Geriatrics Education. 25(4). 109–129. 7 indexed citations

19.

Russell, Jeffrey A., Hai T. Tran, Diana Quinlan, et al.. (2002). Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomes. Biology of Blood and Marrow Transplantation. 8(9). 468–476. 220 indexed citations

20.

Bewick, Mary A., Michael Conlon, Robert M. Lafrenie, et al.. (1999). Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support. Bone Marrow Transplantation. 24(4). 377–384. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact